Nuvectis Pharma, Inc. NVCT Business Segments — Net Income Loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Nuvectis Pharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nuvectis Pharma, Inc.'s business segments — net income loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nuvectis Pharma, Inc.'s business segments — net income loss?
- Nuvectis Pharma, Inc. (NVCT) reported business segments — net income loss of -$6.05M in Q1 2026.
- How has Nuvectis Pharma, Inc.'s business segments — net income loss changed year-over-year?
- Nuvectis Pharma, Inc.'s business segments — net income loss decreased by 13.5% year-over-year, from -$5.33M to -$6.05M.
- What does business segments — net income loss mean?
- The bottom-line financial result for the clinical development segment, calculated as segment revenue minus segment-specific operating expenses. For early-stage biopharmaceutical companies, this typically represents the cash burn rate associated with R&D activities.